196 related articles for article (PubMed ID: 12559807)
1. The cost-effectiveness of routine childhood varicella vaccination in Germany.
Banz K; Wagenpfeil S; Neiss A; Goertz A; Staginnus U; Vollmar J; Wutzler P
Vaccine; 2003 Mar; 21(11-12):1256-67. PubMed ID: 12559807
[TBL] [Abstract][Full Text] [Related]
2. The economic value of childhood varicella vaccination in France and Germany.
Coudeville L; Brunot A; Szucs TD; Dervaux B
Value Health; 2005; 8(3):209-22. PubMed ID: 15877593
[TBL] [Abstract][Full Text] [Related]
3. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany.
Wutzler P; Neiss A; Banz K; Goertz A; Bisanz H
Med Microbiol Immunol; 2002 Oct; 191(2):89-96. PubMed ID: 12410347
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of a routine varicella vaccination program for US children.
Lieu TA; Cochi SL; Black SB; Halloran ME; Shinefield HR; Holmes SJ; Wharton M; Washington AE
JAMA; 1994 Feb; 271(5):375-81. PubMed ID: 8283587
[TBL] [Abstract][Full Text] [Related]
5. Varicella vaccination in Italy : an economic evaluation of different scenarios.
Coudeville L; Brunot A; Giaquinto C; Lucioni C; Dervaux B
Pharmacoeconomics; 2004; 22(13):839-55. PubMed ID: 15329030
[TBL] [Abstract][Full Text] [Related]
6. An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland.
Ahern S; Browne J; Murphy A; Teljeur C; Ryan M
Vaccine; 2024 May; 42(14):3321-3332. PubMed ID: 38609807
[TBL] [Abstract][Full Text] [Related]
7. [Impact of universal varicella vaccination in Germany: an epidemiological and economic analysis].
Knuf M; Neiss A; Wutzler P
Klin Padiatr; 2006; 218(4):203-12. PubMed ID: 16819701
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule.
Scuffham P; Devlin N; Eberhart-Phillips J; Wilson-Salt R
Soc Sci Med; 1999 Sep; 49(6):763-79. PubMed ID: 10459888
[TBL] [Abstract][Full Text] [Related]
9. Cost-benefit analysis of routine childhood vaccination against chickenpox in Taiwan: decision from different perspectives.
Hsu HC; Lin RS; Tung TH; Chen TH
Vaccine; 2003 Sep; 21(25-26):3982-7. PubMed ID: 12922134
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases.
Bonanni P; Boccalini S; Bechini A; Banz K
Vaccine; 2008 Oct; 26(44):5619-26. PubMed ID: 18723062
[TBL] [Abstract][Full Text] [Related]
11. Economic burden of varicella in Singapore--a cost benefit estimate of implementation of a routine varicella vaccination.
Jean-Jasmin LM; Lynette SP; Stefan M; Kai CS; Chew FT; Wah LB
Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):693-6. PubMed ID: 15689089
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness and budget impact of universal varicella vaccination in Russia.
Marijam A; Safonova E; Scherbakov M; Shpeer E; Van Oorschot D; Rudakova A; Tatochenko V; Briko N
Hum Vaccin Immunother; 2022 Nov; 18(5):2045152. PubMed ID: 35258445
[TBL] [Abstract][Full Text] [Related]
13. Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varicella? A model-based study for Italy.
Holl K; Sauboin C; Amodio E; Bonanni P; Gabutti G
BMC Public Health; 2016 Oct; 16(1):1103. PubMed ID: 27769206
[TBL] [Abstract][Full Text] [Related]
14. Empirical data on the varicella situation in Germany for vaccination decisions.
Wagenpfeil S; Neiss A; Banz K; Wutzler P
Clin Microbiol Infect; 2004 May; 10(5):425-30. PubMed ID: 15113320
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of varicella vaccination in Swiss children and adolescents.
Banz K; Iseli A; Aebi C; Brunner M; Schmutz AM; Heininger U
Hum Vaccin; 2009 Dec; 5(12):847-57. PubMed ID: 19829048
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil.
Valentim J; Sartori AM; de Soárez PC; Amaku M; Azevedo RS; Novaes HM
Vaccine; 2008 Nov; 26(49):6281-91. PubMed ID: 18674582
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of varicella vaccination in Canada.
Brisson M; Edmunds WJ
Vaccine; 2002 Jan; 20(7-8):1113-25. PubMed ID: 11803072
[TBL] [Abstract][Full Text] [Related]
18. Costs and benefits of routine varicella vaccination in German children.
Beutels P; Clara R; Tormans G; Van Doorslaer E; Van Damme P
J Infect Dis; 1996 Nov; 174 Suppl 3():S335-41. PubMed ID: 8896542
[TBL] [Abstract][Full Text] [Related]
19. Validation of health economic models: the example of EVITA.
Hammerschmidt T; Goertz A; Wagenpfeil S; Neiss A; Wutzler P; Banz K
Value Health; 2003; 6(5):551-9. PubMed ID: 14627061
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of varicella vaccine programs for Australia.
Scuffham PA; Lowin AV; Burgess MA
Vaccine; 1999 Oct; 18(5-6):407-15. PubMed ID: 10519929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
